National Non-Hodgkin Lymphoma Audit Report 2024 (NNHLA)
The National Non-Hodgkin Lymphoma Audit (NNHLA), part of the National Cancer Audit Collaborating Centre (NATCAN), has published a State of the Nation 2024 report on care received by people diagnosed with non-Hodgkin lymphoma (NHL) in England (2020-2021) and Wales (2022).
Providing a national perspective on the patterns of NHL care and outcomes, this report finds that there is substantial variation across trusts/hospitals in the diagnostic and treatment pathway. Key findings include the fact that 1-year survival rates were almost 20% higher in absolute terms for people with low-grade lymphoma compared to people with high-grade lymphoma in England and Wales. Overall survival rates were similar across nations and years.
It also contains five recommendations:
- Identify and address factors delaying people with NHL being discussed by a haematology or lymphoma multidisciplinary team (MDT)
- Identify pathway factors contributing to delays in people with high-grade NHL starting chemotherapy within 62 days of referral to develop strategies for process improvement
- Identify patient and hospital factors contributing to delays in radiotherapy delivery since last administered dose of chemotherapy
- Ensure adequate resource allocation for data provision
- Deliver more comprehensive cancer data in Wales, with particular focus on chemotherapy and radiotherapy regimens and delivery.
Read the full report: You can view the report by clicking the button below.
Stay up-to-date: For notifications of future reports from HQIP, sign up to our mailing list.
This report was originally published on 12th September 2024. Version 2: Report updated to correct two typographical errors in columns 1 and 3 of Recommendation 3 in the table on page 7.
